Literature DB >> 31574514

Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey.

Hidenori Ohkubo1, Tsutomu Yoshihara1, Noboru Misawa1, Keiichi Ashikari1, Akiko Fuyuki1, Tetsuya Matsuura1, Takuma Higurashi1, Kento Imajo1, Kunihiro Hosono1, Masato Yoneda1, Noritoshi Kobayashi2, Satoru Saito1, Atsushi Nakajima3.   

Abstract

INTRODUCTION: Chronic constipation (CC) is a highly prevalent functional bowel disorder with low treatment satisfaction and impaired quality of life (QOL). However, physicians tend to emphasize only "stool frequency," and relationship between "stool form" and QOL remains unclear. In this study, we aimed to investigate the actual situation of CC treatment in Japan and elucidate the relationship between stool form and QOL in patients with CC.
METHODS: We conducted an online questionnaire survey in September 2018 targeting Japanese adult patients already diagnosed with CC and taking prescribed drugs. Assessments included the type of drug treatment, treatment duration, frequency of drug use, frequency of bowel movements (BMs), Bristol Stool Form Scale (BSFS), and Japanese version of the Patient Assessment of Constipation QOL (PAC-QOL) scores. Relationship between BSFS and Japanese PAC-QOL scores was analyzed, and most important factor that influences QOL was investigated.
RESULTS: A total of 614 subjects were enrolled. Of these, 398 (64.8%) regularly used magnesium oxide and 162 (26.4%) used stimulant laxative, especially 81 (50.0%) used stimulant laxative "everyday." Mean score of the PAC-QOL was 1.29 ± 0.74, and the lowest score (highest QOL) of 0.94 ± 0.61 was observed in BSFS type 4. Significant difference was seen between BSFS type 4 and all the other types except type 7. Multivariate analysis revealed that normal stool form (BSFS type 4) and BMs ≥3/week are strongly related to decreases of PAC-COL score. In BSFS types 6 and 7, 36% of individuals experienced self-discontinuation of prescribed drugs and 53% self-reduced drug intake because of excessive effects.
CONCLUSIONS: Stool form and frequency of BMs are relevant to QOL, especially normal stool form (BSFS type 4) is important for improving the QOL in patients with constipation. Physicians should focus on "stool form" and reconsider the prescription especially in BSFS types 6-7 patients.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Bristol stool form scale; Chronic constipation; Internet survey; Quality of life

Year:  2019        PMID: 31574514     DOI: 10.1159/000502815

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.

Authors:  Kosuke Tanaka; Takaomi Kessoku; Atsushi Yamamoto; Kota Takahashi; Yuki Kasai; Anna Ozaki; Michihiro Iwaki; Takashi Kobayashi; Tsutomu Yoshihara; Noboru Misawa; Takayuki Kato; Jun Arimoto; Akiko Fuyuki; Eiji Sakai; Takuma Higurashi; Hideyuki Chiba; Kunihiro Hosono; Masato Yoneda; Tomoyuki Iwasaki; Takeo Kurihashi; Machiko Nakatogawa; Ayao Suzuki; Masataka Taguri; Shunsuke Oyamada; Keisuke Ariyoshi; Noritoshi Kobayashi; Yasushi Ichikawa; Atsushi Nakajima
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

2.  Internet Survey of Japanese Patients With Chronic Constipation: Focus on Correlations Between Sleep Quality, Symptom Severity, and Quality of Life.

Authors:  Sayuri Yamamoto; Yurika Kawamura; Kazuhiro Yamamoto; Yoshiharu Yamaguchi; Yasuhiro Tamura; Shinya Izawa; Hiroaki Nakagawa; Yoshinori Wakita; Yasutaka Hijikata; Masahide Ebi; Yasushi Funaki; Wataru Ohashi; Naotaka Ogasawara; Makoto Sasaki; Masato Maekawa; Kunio Kasugai
Journal:  J Neurogastroenterol Motil       Date:  2021-10-30       Impact factor: 4.924

3.  Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance.

Authors:  Atsushi Nakajima; Mio Fujimaki; Yuki Arai; Kento Emori
Journal:  J Neurogastroenterol Motil       Date:  2022-07-30       Impact factor: 4.725

4.  Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.

Authors:  Yoshiaki Hishida; Yoshio Nagai; Hidekazu Tsukiyama; Yuta Nakamura; Tomoko Nakagawa; Sonoko Ishizaki; Yasushi Tanaka; Masakatsu Sone
Journal:  Adv Ther       Date:  2022-07-22       Impact factor: 4.070

5.  Prune Juice Containing Sorbitol, Pectin, and Polyphenol Ameliorates Subjective Complaints and Hard Feces While Normalizing Stool in Chronic Constipation: A Randomized Placebo-Controlled Trial.

Authors:  Taishi Koyama; Naoyoshi Nagata; Kengo Nishiura; Naoki Miura; Takashi Kawai; Hirotaka Yamamoto
Journal:  Am J Gastroenterol       Date:  2022-08-12       Impact factor: 12.045

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.